Table 8.
Groups | Age (years) | Presence of CoV-2 antibody in females (n/%) | Presence of CoV-2 antibody (%) in males (n/%) |
---|---|---|---|
1a (first wave) infected | 18–40 | 7 (100%) | 9 (90%) |
40 + | 1 (100%) | 0 | |
1b (second wave) infected | 18–40 | 20 (91%) | 46 (100%) |
40 + | 14 (93%) | 21 (91%) | |
2a Only vaccinated (Vaccine-A) |
18–40 | 11 (85%) | 26 (74%) |
40 + | 21 (88%) | 60 (85%) | |
2b Only vaccinated (Vaccine-B) |
18–40 | 31 (74%) | 163 (94%) |
40 + | 28 (77%) | 219 (87%) | |
2c Only vaccinated (Vaccine-C) |
18–40 | 1 (100%) | 0 |
40 + | 1 (100%) | 0 | |
2d Only vaccinated (Vaccine-D) |
18–40 | 0 | 2 (100%) |
40 + | 2 (100%) | 0 | |
3a (infected + vaccinated |
18–40 | 13 (100%) | 26 (96%) |
40 + | 23 (96%) | 39 (98%) | |
3b (infected + vaccinated) |
18–40 | 9 (90%) | 40 (95%) |
40 + | 14 (100%) | 67 (100%) | |
4 (not infected + not vaccinated) |
18–40 | 16 (84%) | 27 (66%) |
40 + | 5 (83%) | 24 (73%) | |
5a (random) | 18–40 | 29 (63%) | 234 (69%) |
40 + | 06 (46%) | 36 (50%) | |
5b (random) | 18–40 | 69 (40%) | 45 (51%) |
40 + | 38 (56%) | 42 (57%) |